Celsion Corporation (CLSN) news stock charts
Celsion Corporation (CLSN) Investment Summary:
Certain of the statements contained in this Annual Report on Form 10-K are forward-looking and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and other aspects of our present and future business operations and similar matters that also constitute such forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f28%2f0001047469-08-003658.html#FIS_BUSINESS"www.celsion.com
Founded in 1982
CELSION CORP (CLSN:NASDAQ)
LAST $4.55 USD
CHANGE TODAY +0.30 7.06%
VOLUME 95.7K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of CELSION CORP (CLSN)
|
OPEN
$4.25
|
PREVIOUS CLOSE
$4.25
|
|
|
DAY HIGH
$4.64
|
DAY LOW
$4.25
|
|
|
52 WEEK HIGH
09/23/09 - $5.25
|
52 WEEK LOW
03/20/09 - $2.31
|
|
|
MARKET CAP
55.6M
|
AVERAGE VOLUME 10 D
106.9K
|
|
|
EPS TTM
$-1.46
|
SHARES OUTSTANDING
12.2M
|
|
|
CLSN Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Stocks Slump on Subprime Worries
06/22/2007 8:50 AM ET
Major indexes each tumbled more than 1% Friday. One pro wondered whether the hoopla over the Blackstone IPO signaled a market top
Key developments for CELSION CORP (CLSN)
Celsion Corp. Plans to Launch Phase II Program to Study ThermoDox(R) in Combination with RFA for Colorectal Liver Metastases
03/1/2010
Celsion Corp. announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDoxR) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study. In addition to Montefiore Medical Center, at least 2 other leading research institutions from North America and the Asia Pacific region (including Japan) will be included in the Phase II study, which is expected to commence in the second half of 2010. The study is meant to address the growing unmet medical need of colorectal liver metastases, which is globally prevalent and is currently treated by radiofrequency ablation. ThermoDox in combination with hyperthermia or ablation has the potential to provide local tumor control, extending and improving the quality of life. ThermoDox is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer and liver cancer. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor. For primary liver cancer, ThermoDox is being evaluated in a 600-patient global Phase III study at 70 clinical sites under an FDA Special Protocol Assessment. The primary endpoint for the study is progression-free survival and enrollment is expected to be completed in 2010. For recurrent chest wall breast cancer, ThermoDox is being evaluated in a Phase I/II open-label, dose escalating trial that is designed to measure durable local complete response at the tumor site. Celsion expects to enroll approximately 100 patients across the United States and to complete the study by the first half of 2010.
Celsion Corp. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on February 18, 2010).
02/18/2010
Celsion Corp. expected to Report Q1 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on February 18, 2010).
Celsion Corp. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2009
02/17/2010
Celsion Corp. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported loss from operations of $3,818,000, net loss before income taxes of $3,074,000 and net loss of $2,268,000 or $0.19 per basic and diluted share compared to the loss from operations of $1,541,000, net loss before income taxes of $934,000 and net loss of $934,000 or $0.09 per basic and diluted share on licensing revenues of $2,500,000 for the same quarter year ago. For the year, the company reported loss from operations of $17,008,000, net loss before income taxes of $15,999,000 and net loss of $15,193,000 or $1.43 per basic and diluted share compared to the loss from operations of $11,548,000, net loss before income taxes of $11,786,000 and net loss of $11,786,000 or $1.16 per basic and diluted share on licensing revenues of $2,500,000 for the previous year.
Celsion Corporation financial resources
CLSN Competitors
| Company | Last | Change |
| BSD Medical Corp | $1.80 USD | +0.03 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | CLSN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 5.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
CLSN |
||
|
CLSN transactions
| Type Date |
Target |
|
Private Placement
September 25, 2009 |
-- |
More Recent Financial News About Celsion Corporation
Celsion Corporation Announces ThermoDox(R) Abstract Accepted for Presentation at the American Society of Clinical Oncology 2010 Annual Meeting
2010-03-18 08:11:26
Quote: Â The abstract, titled "Phase I/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of approved hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall" will be presented by Nicholas Borys, M.D., Celsion's Chief Medical Officer."We are pleased that our study was among those that were accepted providing continued evidence of the medical community's high interest level in ThermoDox, the progress of...Read article
CELSION CORP Files SEC form 10-K, Annual Report
2010-03-18 08:11:26
Quote: ITEM 6.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Overview
Celsion is an innovative oncology drug development company focused on
improving treatment for those suffering with aggressive and difficult to treat
forms of cancer. We are working to develop and commercialize more efficient,
effective, targeted chemotherapeutic oncology drugs based on our proprietary
heat-activated liposomal technology. Our lead product ThermoDox® is being tested
in human...Read article
Celsion Plans to Launch Phase II Program to Study ThermoDox(R) in Combination with RFA for Colorectal Liver Metastases
2010-03-03 06:40:28
Quote: Celsion expects to enroll approximately 100 patients across the United States and to complete the study by the first half of 2010. Additional information on these ThermoDox clinical studies may be found at www.celsion.com.ThermoDox® is a registered trademark of Celsion CorporationAbout Colorectal Liver Metastases (CRLM)The American Cancer Society estimates that there were about 147,000 new cases of colorectal cancer and about 50,000 colorectal cancer deaths during 2009. Up to 25% of patients ...Read article
Celsion Plans to Launch Phase II Program to Study ThermoDox(R) in Combination with RFA for Colorectal Liver Metastases
2010-03-02 03:01:24
Quote: Celsion expects to enroll approximately 100 patients across the United States and to complete the study by the first half of 2010. Additional information on these ThermoDox clinical studies may be found at www.celsion.com.ThermoDox® is a registered trademark of Celsion CorporationAbout Colorectal Liver Metastases (CRLM)The American Cancer Society estimates that there were about 147,000 new cases of colorectal cancer and about 50,000 colorectal cancer deaths during 2009. Up to 25% of patients ...Read article
Celsion's Technology Is the Focus of 6.4 Million EUR 'HIFU-CHEM' Program To Study ThermoDox(R) and MRI-guided HIFU
2010-03-01 05:23:45
Quote: Celsion expects to enroll approximately 100 patients across the United States and to complete the study by the first half of 2010. Additional information on these ThermoDox clinical studies may be found at http://www.clinicaltrials.gov.ThermoDox® is a registered trademark of Celsion CorporationAbout Celsion CorporationCelsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with hea...Read article
Celsion's Technology Is the Focus of 6.4 Million EUR 'HIFU-CHEM' Program To Study ThermoDox(R) and MRI-guided HIFU
2010-02-23 07:56:01
Quote: Celsion expects to enroll approximately 100 patients across the United States and to complete the study by the first half of 2010. Additional information on these ThermoDox clinical studies may be found at http://www.clinicaltrials.gov.ThermoDox® is a registered trademark of Celsion CorporationAbout Celsion CorporationCelsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with hea...Read article
Celsion Reports Fourth Quarter and Full Year 2009 Financial Results
2010-02-22 05:22:08
Quote: Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.  "We continue to make substantive progress in our Phase III HEAT trial for ThermoDox with over 45% of the 600 patients now enrolled in the study," said Michael T...Read article
Celsion Reports Fourth Quarter and Full Year 2009 Financial Results
2010-02-18 03:56:30
Quote: Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.  "We continue to make substantive progress in our Phase III HEAT trial for ThermoDox with over 45% of the 600 patients now enrolled in the study," said Michael T...Read article
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition
2010-02-18 03:56:29
Quote: CELSION CORPRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
CELSION CORP
17-Feb-2010Results of Operations and Financial ConditionPrivacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incompleten...Read article
Celsion to Hold Fourth Quarter and Full Year 2009 Financial Results
2010-02-16 08:30:59
Quote: Eastern Time on Wednesday, February 17, 2010http://www.celsion.com.The call will be archived for replay on February 17, 2010 at 3:00 p.m. ET and will remain available until Wednesday, February 24, 2010http://www.celsion.com, for 30 days after 3:00 P.M. ET on Wednesday, February 17, 2010.About Celsion CorporationCelsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activate...Read article
Celsion to Hold Fourth Quarter and Full Year 2009 Financial Results
2010-02-15 05:28:50
Quote: Eastern Time on Wednesday, February 17, 2010http://www.celsion.com.The call will be archived for replay on February 17, 2010 at 3:00 p.m. ET and will remain available until Wednesday, February 24, 2010http://www.celsion.com, for 30 days after 3:00 P.M. ET on Wednesday, February 17, 2010.About Celsion CorporationCelsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activate...Read article
Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
2010-02-15 05:28:50
Quote: 10® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.The DMC for the HEAT study is comprised of an independent group of medical and scientific experts who are responsible for reviewing and evaluating patient safety and efficacy data. The DMC reviews safety data at regular intervals with the mandate to ensure patient safety and monitor the quality and overall conduct of the study. T...Read article
Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
2010-02-11 03:27:41
Quote: 10® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.The DMC for the HEAT study is comprised of an independent group of medical and scientific experts who are responsible for reviewing and evaluating patient safety and efficacy data. The DMC reviews safety data at regular intervals with the mandate to ensure patient safety and monitor the quality and overall conduct of the study. T...Read article
Celsion Abstract Selected for Oral Presentation at 2010 IHPBA World Congress in Buenos Aires, Argentina
2010-01-29 01:04:48
Quote: Ravikumar is currently Director-Cancer Services, Chief Quality Officer-surgery/interventional procedures, and Director-Center for surgical innovation; Geisinger Health System, PA, and continues his work with ThermoDox and RFA as a clinical investigator in Celsion's HEAT study. In this Phase I study, ThermoDox was assessed for safety, pharmacokinetics and tumor response in 12 liver cancer patients (3 with hepatocellular carcinoma (HCC) and 9 with metastatic cancer). Patients were treated with The...Read article
Celsion to Host Research and Development Day in New York City on February 24, 2010
2010-01-29 01:04:47
Quote: 25 /PRNewswire-FirstCall/ -- CELSION CORPORATION (Nasdaq: CLSN) announced today that it will host a Research and Development Day for the financial community on Wednesday, February 24, 2010 from 7:30 AM – 10:30 AM ET in New York Cityhttp://www.celsion.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.Investigator perspectives will be presented by physicians in Medical Oncology, Surgery, and Interve...Read article
Celsion to Host Research and Development Day in New York City on February 24, 2010
2010-01-26 01:46:02
Quote: 25 /PRNewswire-FirstCall/ -- CELSION CORPORATION (Nasdaq: CLSN) announced today that it will host a Research and Development Day for the financial community on Wednesday, February 24, 2010 from 7:30 AM – 10:30 AM ET in New York Cityhttp://www.celsion.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.Investigator perspectives will be presented by physicians in Medical Oncology, Surgery, and Interve...Read article
Celsion Abstract Selected for Oral Presentation at 2010 IHPBA World Congress in Buenos Aires, Argentina
2010-01-22 02:26:43
Quote: Ravikumar is currently Director-Cancer Services, Chief Quality Officer-surgery/interventional procedures, and Director-Center for surgical innovation; Geisinger Health System, PA, and continues his work with ThermoDox and RFA as a clinical investigator in Celsion's HEAT study. In this Phase I study, ThermoDox was assessed for safety, pharmacokinetics and tumor response in 12 liver cancer patients (3 with hepatocellular carcinoma (HCC) and 9 with metastatic cancer). Patients were treated with The...Read article
Celsion Reports Third Quarter 2009 Financial Results and Business Update
2010-01-20 04:41:41
Quote: CLSNNews), a leading oncology drug developmentcompany, announced financial results for the third quarter endedSeptember 30, 2009 and highlighted the progress made in thecommercialization of ThermoDox®, Celsion’s heat activated liposomalencapsulation of doxorubicin for the treatment of hepatocellularcarcinoma (HCC), the most common form of primary liver cancer, andrecurrent chest wall breast cancer.“We achieved key milestones during the quarter against our corporateobjectives to a...Read article
Celsion Announces Treatment of First Patient in China in Global Phase III ThermoDox® Trial for Primary Liver Cancer
2010-01-20 04:41:40
Quote: COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation, a leading oncology drug development company,announced today that the first patient in China has been enrolled andtreated as part of Celsion’s global Phase III ThermoDox HEAT trial forthe treatment of hepatocellular carcinoma (HCC), the most common form ofprimary liver cancer. Following recent regulatory approvals in China,Malaysia and the Philippines, the study is now recruiting patients inten of eleven planned countries, with the major...Read article
Celsion Provides Update on Progress of ThermoDox® Phase III Study for Primary Liver Cancer
2010-01-20 04:41:40
Quote: Followingrecent regulatory approvals in China, Malaysia, Thailand and thePhilippines, the study is now enrolling patients in eleven countries,with the majority of clinical sites located in the Asia Pacific regionwhere HCC is most prevalent.Enrollment in this 600 patient study continues to accelerate and Celsionexpects to meet its objective of completing enrollment by the middle of2010. A pre-planned, un-blinded interim efficacy analysis will beperformed by an independent Data Management Committe...Read article
Would you like to leave a comment about Celsion Corporation CLSN
Find out what social network information about Celsion Corporation are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Celsion Corporation's Stock there is more great penny stock and market information at Realpennies